[go: up one dir, main page]

CL2018002467A1 - El uso de moduladores de receptores de glucocorticoides para potenciar los inhibidores de checkpoint - Google Patents

El uso de moduladores de receptores de glucocorticoides para potenciar los inhibidores de checkpoint

Info

Publication number
CL2018002467A1
CL2018002467A1 CL2018002467A CL2018002467A CL2018002467A1 CL 2018002467 A1 CL2018002467 A1 CL 2018002467A1 CL 2018002467 A CL2018002467 A CL 2018002467A CL 2018002467 A CL2018002467 A CL 2018002467A CL 2018002467 A1 CL2018002467 A1 CL 2018002467A1
Authority
CL
Chile
Prior art keywords
potentiate
glucocorticoid receptor
receptor modulators
checkpoint inhibitors
checkpoint inhibitor
Prior art date
Application number
CL2018002467A
Other languages
English (en)
Inventor
Hazel Hunt
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of CL2018002467A1 publication Critical patent/CL2018002467A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA UN MÉTODO QUE COMBINA UN INHIBIDOR DE CHECKPOINT Y UN MODULADOR DEL RECEPTOR DE GLUCOCORTICOIDES PARA TRATAR CÁNCER, POR EJEMPLO, UN CÁNCER SENSIBLE A UN INHIBIDOR DE CHECKPOINT.
CL2018002467A 2016-03-01 2018-08-29 El uso de moduladores de receptores de glucocorticoides para potenciar los inhibidores de checkpoint CL2018002467A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662302106P 2016-03-01 2016-03-01
US201662320276P 2016-04-08 2016-04-08

Publications (1)

Publication Number Publication Date
CL2018002467A1 true CL2018002467A1 (es) 2018-11-23

Family

ID=59744340

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002467A CL2018002467A1 (es) 2016-03-01 2018-08-29 El uso de moduladores de receptores de glucocorticoides para potenciar los inhibidores de checkpoint

Country Status (14)

Country Link
US (3) US10980797B2 (es)
EP (1) EP3423453A4 (es)
JP (4) JP6847120B2 (es)
KR (1) KR102845317B1 (es)
CN (1) CN109071537B (es)
AU (1) AU2017228329B2 (es)
CA (1) CA3015218A1 (es)
CL (1) CL2018002467A1 (es)
IL (2) IL297201A (es)
MX (1) MX390517B (es)
PH (1) PH12018501848B1 (es)
SG (1) SG11201807421TA (es)
WO (1) WO2017151613A1 (es)
ZA (1) ZA201805787B (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11684612B2 (en) 2019-02-22 2023-06-27 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
US12433882B2 (en) 2022-10-28 2025-10-07 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
KR102845317B1 (ko) 2016-03-01 2025-08-13 코어셉트 쎄라퓨틱스 인코포레이티드 체크포인트 억제제를 강화시키기 위한 글루코코르티코이드 수용체 조정제의 용도
US9943505B2 (en) * 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
KR102342620B1 (ko) * 2017-03-31 2021-12-22 코어셉트 쎄라퓨틱스 인코포레이티드 자궁경부암을 치료하기 위한 글루코코르티코이드 수용체 조정제
US11213526B2 (en) * 2017-06-20 2022-01-04 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
US12377111B2 (en) 2018-09-28 2025-08-05 Kyungpook National University Industry-Academic Cooperation Foundation Composition, comprising thiamine derivative, for prevention or treatment of hypercortisolemia
WO2020097513A1 (en) 2018-11-09 2020-05-14 Corcept Therapeutics Incorporated Methods for shrinking pituitary tumors
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
WO2020132046A1 (en) * 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
SG11202105770YA (en) * 2018-12-19 2021-07-29 Corcept Therapeutics Inc Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
EP4045045A4 (en) * 2019-10-16 2023-11-22 Corcept Therapeutics Incorporated METHOD FOR NORMALIZING THE RATIO BETWEEN NEUTROPHILS AND LYMPHOCYTES IN CANCER PATIENTS USING A SELECTIVE GLUCOCORTICOID RECEPTOR ANTAGONIST
PH12022551938A1 (en) * 2020-01-29 2023-10-23 Corcept Therapeutics Inc TREATMENT OF ADRENOCORTICAL CARCINOMA WITH SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS (SGRMs) AND ANTIBODY CHECKPOINT INHIBITORS
KR20220140567A (ko) * 2020-02-10 2022-10-18 코어셉트 쎄라퓨틱스 인코포레이티드 선택적 글루코코르티코이드 수용체 조절제를 사용하여 항-종양 반응을 자극하는 방법
AU2021282256A1 (en) * 2020-05-27 2022-12-15 Corcept Therapeutics Incorporated Concomitant administration of glucocorticoid receptor modulator relacorilant and CYP2C8 substrates
WO2021242916A1 (en) * 2020-05-27 2021-12-02 Corcept Therapeutics Incorporated Concomitant administration of glucocorticoid receptor modulator relacorilant and cyp2c9 substrates
WO2022134033A1 (en) * 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CN118891062A (zh) * 2021-12-03 2024-11-01 得克萨斯大学体系董事会 用米非司酮阻断糖皮质激素受体使胰腺癌对免疫疗法敏感
CN119997939A (zh) 2022-10-06 2025-05-13 科赛普特治疗公司 糖皮质激素受体调节剂的制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070893A2 (en) 2004-01-09 2005-08-04 Corcept Therapeutics, Inc. Azadecalin glucocorticoid receptor modulators
ATE407934T1 (de) 2004-03-09 2008-09-15 Corcept Therapeutics Inc Azadecalinverbindungen mit kondensiertem ring als glucocorticoidrezeptormodulatoren
EP2429529B1 (en) 2009-05-12 2015-01-14 Corcept Therapeutics, Inc. Solid forms and process for preparing
US8710035B2 (en) * 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
MX2013010576A (es) 2011-03-15 2014-03-12 Abbvie Inc Moduladores de receptores de hormonas nucleares.
WO2013039916A1 (en) * 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
EP2763680A4 (en) * 2011-10-04 2015-05-20 Invivis Pharmaceuticals Inc METHODS AND SYSTEMS FOR IDENTIFYING AND TREATING ANTIPROGESTIN-SENSITIVE TUMORS
WO2013169971A1 (en) * 2012-05-10 2013-11-14 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
JP6172871B2 (ja) * 2012-05-25 2017-08-02 コーセプト セラピューティクス， インコーポレイテッド ヘテロアリール‐ケトン縮合アザデカリン糖質コルチコイドレセプター調節因子
US8859774B2 (en) * 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
SI2892927T1 (sl) * 2012-09-07 2018-10-30 Regeneron Pharmaceuticals,Inc Metode zdravljenja atopijskega dermatitisa z dajanjem antagonista Il-4R
TWI633891B (zh) * 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
JP6508785B2 (ja) * 2013-10-25 2019-05-08 ファーマサイクリックス エルエルシー ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置
CN105848674A (zh) * 2013-11-11 2016-08-10 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
WO2015077414A1 (en) * 2013-11-20 2015-05-28 Dana-Farber Cancer Institute, Inc. Kynurenine pathway biomarkers predictive of anti-immune checkpoint inhibitor response
RU2674983C1 (ru) * 2013-11-25 2018-12-14 Корсепт Терапеутикс, Инк. Октагидро конденсированные азадекалиновые модуляторы глюкокортикоидного рецептора
EP3082853A2 (en) * 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
MA39211B1 (fr) 2013-12-24 2019-01-31 Bristol Myers Squibb Co Composés tricycliques comme agents anti-cancers
WO2015181343A2 (en) * 2014-05-30 2015-12-03 Ventana Medical Systems, Inc. Multiplex assay for improved scoring of tumor tissues stained for pd-l1
JP6802172B2 (ja) 2015-01-30 2020-12-16 オンコシューティクス インコーポレイテッドＯｎｃｏｃｅｕｔｉｃｓ，Ｉｎｃ． ７−ベンジル−４−（２−メチルベンジル）−２，４，６，７，８，９−ヘキサヒドロイミダゾ［１，２−ａ］ピリド［３，４−ｅ］ピリミジン−５（１ｈ）−オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法
US20180064679A1 (en) * 2015-03-05 2018-03-08 Abraxis Bioscience, Llc Method for treating cancer based on level of glucocorticoid receptor
KR102845317B1 (ko) 2016-03-01 2025-08-13 코어셉트 쎄라퓨틱스 인코포레이티드 체크포인트 억제제를 강화시키기 위한 글루코코르티코이드 수용체 조정제의 용도
EP3612181A4 (en) 2017-04-21 2021-01-06 Epizyme, Inc. Combination therapies with ehmt2 inhibitors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11684612B2 (en) 2019-02-22 2023-06-27 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
US12097192B2 (en) 2019-02-22 2024-09-24 Corcept Therapeutics Incorpoarted Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
US12433882B2 (en) 2022-10-28 2025-10-07 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant

Also Published As

Publication number Publication date
CN109071537A (zh) 2018-12-21
CA3015218A1 (en) 2017-09-08
US20210205294A1 (en) 2021-07-08
EP3423453A4 (en) 2019-11-06
BR112018067330A2 (pt) 2019-01-22
US20250073224A1 (en) 2025-03-06
CN109071537B (zh) 2024-07-05
IL297201A (en) 2022-12-01
IL261502A (en) 2018-10-31
JP2025028214A (ja) 2025-02-28
MX2018010564A (es) 2018-11-09
MX390517B (es) 2025-03-20
SG11201807421TA (en) 2018-09-27
NZ745540A (en) 2025-03-28
JP2019023228A (ja) 2019-02-14
EP3423453A1 (en) 2019-01-09
JP2023060061A (ja) 2023-04-27
AU2017228329A1 (en) 2018-09-06
KR20180116372A (ko) 2018-10-24
US20190083486A1 (en) 2019-03-21
JP6847120B2 (ja) 2021-03-24
US12171760B2 (en) 2024-12-24
AU2017228329B2 (en) 2021-03-11
JP2019507159A (ja) 2019-03-14
PH12018501848A1 (en) 2019-01-28
ZA201805787B (en) 2020-05-27
WO2017151613A1 (en) 2017-09-08
KR102845317B1 (ko) 2025-08-13
US10980797B2 (en) 2021-04-20
PH12018501848B1 (en) 2024-02-23
IL261502B (en) 2022-11-01
IL261502B2 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
CL2018002467A1 (es) El uso de moduladores de receptores de glucocorticoides para potenciar los inhibidores de checkpoint
CL2019002314A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
MX2018013593A (es) Terapias combinadas de inhibidores de hdac e inhibidores de pd-l1.
CL2019002108A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
CO2019001212A2 (es) Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos
CL2019002112A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
CO2018013298A2 (es) Anticuerpos anti-gitr y sus usos.
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
CL2018000687A1 (es) Nuevos compuestos bicíclicos como inhibidores de atx.
BR112018013995A2 (pt) terapia de combinação de vírus oncolítico e inibidor de ponto de verificação
MX2018005528A (es) Inhibidores de ret.
ECSP17023281A (es) Inhibidores de mk2 y sus usos
CL2016000400A1 (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica.
CR20170219A (es) Inhibidores del bromodominio
CL2015003200A1 (es) Potenciador de inhibidores del homólogo de zeste
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CL2015002151A1 (es) Biaril amide compuestos como inhibidores de quinasa
MX2016010080A (es) Combinacion de un antagonista de muerte programada-1 y un inhibidor de indolamina 2,3-dioxigenasa 1 para el tratamiento del cancer.
BR112017024555A2 (pt) moduladores de ccr2
MX2017016041A (es) Metodos para usar activadores de piruvato cinasa.
CL2018001252A1 (es) Métodos para tratar esclerosis múltiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton
BR112019004123A2 (pt) sistemas e métodos para atuar dispositivos hidraulicamente atuados
CL2015002113A1 (es) Compuestos de azetidinloxifenilpirrolidina
CO2017002356A2 (es) Métodos para tratar la depresión usando moduladores de nmda